We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure

By LabMedica International staff writers
Posted on 02 Aug 2023
Print article
Image: Monitoring of changes in longitudinal urine patterns can help predict heart failure (credit: R.Sakaniwa at el., European Journal of Heart Failure, 2023)
Image: Monitoring of changes in longitudinal urine patterns can help predict heart failure (credit: R.Sakaniwa at el., European Journal of Heart Failure, 2023)

Heart failure, a condition that will affect one in five individuals during their lifetime, is significantly associated with kidney impairments. As such, monitoring kidney health indicators in individuals susceptible to heart failure is standard practice. While short-term fluctuations in renal biomarkers are well-established, the link between long-term biomarker patterns and heart failure risk is yet to be understood. Now, researchers have discovered a key treatment target that could potentially prevent patients from developing serious heart conditions in the future.

In a new study, an international research team led by Osaka University (Suita, Japan) has successfully identified long-term trends in kidney health indicators among healthy European adults, and how these patterns influence the risk of new-onset heart failure. The research involved the examination of two prevalent kidney health markers—urinary albumin excretion (UAE) and serum creatinine—in nearly 7000 participants from the Dutch study Prevention of Renal and Vascular End-stage Diseases (PREVEND). The team monitored the trends in UAE and serum creatinine levels over an 11-year period, investigating their correlation with new-onset heart failure and death.

The study clearly revealed that the majority of participants exhibited stable low UAE or serum creatinine levels, but those with consistently high UAE were at a significantly increased risk of new-onset heart failure or all-cause mortality. Interestingly, annual levels of renal biomarkers remained notably stable year after year throughout the 11-year follow-up period. Stable serum creatinine levels over time correlated with heart failure, but not with an elevated risk of death. A more in-depth analysis revealed that individuals with consistently higher UAE or serum creatinine levels were more likely to be older, male, and to have conditions like diabetes, previous heart attack, or dyslipidemia. The study implies that reducing UAE could help decrease the risk of future heart failure and death in these patients. Given that heart failure is likely to affect one in five people during their lifetime, these findings could significantly influence preventive medicine and further validation of these results is required in non-European populations.

“Our results highlight the importance of the heart-kidney link in heart failure by showing that patients with persistently worse renal function, as indicated by higher UAE or serum creatinine levels, are at a higher risk of heart failure or mortality,” said Dr. Ryoto Sakaniwa, lead author of the study. “Reducing these renal biomarkers could help prevent heart failure.”

Related Links:
Osaka University

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Pipet Controller
Stripettor Pro
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.